Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2012-03-05 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 85% confidence The document is a research publication from DZ BANK AG regarding Evotec. It contains financial estimates, investment ratings (Kaufen), and detailed analysis of the company's performance and outlook. It is not an official company filing (like a 10-K or IR) but rather an external analyst report. Since the provided categories do not include 'Analyst Report' or 'Research Note', and it does not fit the criteria for official corporate filings, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous financial documents. FY 2011
2012-03-05 German
German Science Day, Berlin
Investor Presentation Classification · 98% confidence The document text consists of slides detailing Evotec's capabilities, focus areas (Oncology Drug Discovery), pipeline, and existing partnerships/alliances. The structure, use of bullet points, section headers like 'Evotec at a glance', 'Deep clinical pipeline', and 'Current oncology alliances', strongly indicates this is a presentation deck intended for investors or potential partners. This aligns best with the Investor Presentation (IP) category, which covers detailed presentations on financials, strategy, and market position.
2012-02-17 English
Evotec and IR Pharma Establish Drug Discovery Alliance in the Field of Respiratory
Regulatory Filings Classification · 100% confidence The document is a short corporate news release dated February 16, 2012, announcing an 'exclusive strategic alliance' between Evotec AG and IR Pharma regarding drug discovery in respiratory diseases. It details the nature of the collaboration and includes quotes from management but explicitly states 'No financial details were disclosed.' This type of announcement, which is a specific corporate event update (an alliance/partnership) that doesn't fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS), is best classified as a general Regulatory Filing or Corporate News announcement. Given the options, 'Regulatory Filings (RNS)' serves as the appropriate fallback for miscellaneous corporate news that isn't a standard financial report or a specific action like a director's dealing or dividend notice. It is not an M&A activity (TAR) as it is an alliance, not a takeover/merger.
2012-02-16 English
Report Publication Announcement 2012
Report Publication Announcement Classification · 100% confidence The document is very short (2593 characters) and its primary purpose is to announce the future disclosure dates for several financial reports, including the 'Annual financial report', 'Financial report (half-year)', and 'Quarterly financial report'. It explicitly states that these reports 'shall be disclosed' on future dates and provides links to where they will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement detailing the publication of reports classifies as a Report Publication Announcement (RPA), not the report itself (like 10-K or IR).
2012-02-02 English
Evotec completes squeeze-out process for DeveloGen
M&A Activity Classification · 99% confidence The document announces the completion of a 'squeeze-out process' by Evotec AG to acquire all remaining shares of DeveloGen AG. This action involves a change in ownership structure and capital control, specifically related to the acquisition of shares following a prior majority holding. This type of corporate action, dealing with the acquisition/consolidation of ownership, fits best under Capital/Financing Update (CAP) or potentially Transaction in Own Shares (POS) if viewed as a final acquisition step. However, since it is a formal corporate action resulting in 100% ownership following a shareholder vote, it is fundamentally a capital structure change. Given the options, 'Capital/Financing Update (CAP)' is the most appropriate classification for a squeeze-out completion announcement, as it finalizes a significant change in the capital structure of the subsidiary. It is not an ER (no financial results), 10-K (not annual report), CT (not a transcript), or DVA (it's the action, not just the voting result announcement). It is a specific corporate transaction announcement.
2012-01-24 English
Evotec and Harvard University Expand Strategic Alliance into Kidney Disease
Environmental & Social Information Classification · 99% confidence The document is a press release dated January 17, 2012, announcing a strategic alliance expansion between Evotec AG and Harvard University/Brigham and Women's Hospital regarding kidney disease research. It contains standard corporate news formatting, including contact information and a dissemination notice from DGAP (a German news distribution service). This type of announcement, detailing a business development (alliance/partnership) that is not a core financial report (10-K, IR, ER) or a specific regulatory filing like insider trading (DIRS) or capital change (CAP), fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate announcement, or potentially 'LTR' if it were a legal matter, but here it is a business development. Given the options, RNS serves as the best general catch-all for non-standard corporate news releases that are not explicitly defined elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a specific financial/governance document.
2012-01-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.